Navigation Links
GlaxoSmithKline Consumer Healthcare to Reach 85 Percent of the World's Smokers with Quit Aids
Date:3/9/2009

Experts convene at World Conference on Tobacco OR Health meeting to discuss reducing global tobacco use and accessibility to treatment options

MUMBAI, India, March 9 /PRNewswire/ -- GlaxoSmithKline (GSK) Consumer Healthcare today announced plans to increase the availability of their therapeutic nicotine products to reach more than 800 million people world-wide over the next four years. The announcement was made at the World Conference on Tobacco OR Health (WCTOH) meeting held this year in India, a country on pace to see nearly one million smoking-related deaths per year by 2010(1). Thought leaders from around the globe gather at this triannual conference to discuss global initiatives under way to reduce tobacco use and its extraordinary health toll.

"GSK plans to introduce our quit smoking aids to 85 percent of the world's smokers by 2013. We are committed to finding approaches, in concert with local experts, to maximize the access and impact of our life-saving products," said Raj Mishra, MD, PhD, vice president research and development, GlaxoSmithKline Consumer Healthcare. "Our hope is that by launching our therapeutic nicotine products globally we will be doing our part to help reduce the global burden from tobacco-related disease by helping more smokers quit."

A World Health Organization (WHO) global tobacco report found that tobacco use was increasing most rapidly in low-income countries due to steady population growth coupled with tobacco industry efforts. In fact, the report states that without a commitment to helping smokers quit, a projected one billion smokers will die prematurely from tobacco this century(2). As part of their outlined policy, the WHO encourages leaders in the fight against tobacco to offer help to quit tobacco use through three types of treatment - telephone counselling, cessation advice in primary healthcare services and pharmacotherapy including the use of therapeutic nicotine(2).

"Many smokers around the world want to quit, but do not have the necessary information or resources to do so effectively. Increasing the accessibility of products designed to help smokers quit is a positive step towards a smoke-free world," said Dr. Randeep Guleria, professor, Department of Medicine, All India Institute of Medical Sciences. "With their recently passed ban on smoking in enclosed public places, India's government is sending a strong message to its more than 120 million adult smokers(1) that they are serious about stemming the persistent widespread tobacco use in India. Encouraging the use of cessation aids such as therapeutic nicotine is the next step towards ridding this country of a perilous health issue."

The global implications of continued tobacco use are staggering:

  • Tobacco use is the number one preventable cause of death and disease, projected to cause one billion deaths in the 21st century unless effective interventions are implemented(2).
  • More than one in three adults worldwide (more than 1.1 billion people) smokes, 80 percent of whom live in low- and middle-income countries(2).
  • If current smoking patterns continue, it will cause some 10 million deaths each year by 2020 and 70 percent of these will occur in developing countries(2).
  • In the United Sates alone, tobacco dependence costs the nation almost $200 billion - more than $96 billion per year in direct medical expenses and $97 billion in lost productivity(3).

Safety and Efficacy of GlaxoSmithKline's Therapeutic Nicotine

Therapeutic nicotine including the NiQuitin lozenge and patch (brand name Nicabate in Australia) can help relieve withdrawal symptoms during smoking cessation(3). Research from more than 110 clinical trials involving over 40,000 participants have established the safety and efficacy profile of therapeutic nicotine products when used as directed(4). Therapeutic nicotine is recommended as a first-line treatment for smoking addiction in United States, United Kingdom and World Health Organization (WHO) guidelines(2,3,5). To date, GSK's therapeutic nicotine has helped more than six million people around the world quit smoking, and as a result, has greatly reduced their exposure to the risks of cancer and other smoking-related diseases(6).

These products are designed specifically to break the addiction cycle by offering a gradual, controlled delivery of nicotine to the body, helping to relieve withdrawal symptoms.

About GlaxoSmithKline Consumer Healthcare

GlaxoSmithKline Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. Its more than 30 well-known brands include the leading smoking cessation products, NicoDerm(R) CQ and Commit(R), NiQuitin and Nicabate, as well as many medicine cabinet staples such as Aquafresh(R), Panadol(R), Crocin(R), Horlicks(R) and Sensodyne(R). GlaxoSmithKline Consumer Healthcare continues to develop innovative products to help all smokers find their best support system and achieve their goal of being cigarette free.

About GlaxoSmithKline

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and consumer healthcare companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

(1) Jha, et al; A Nationally Representative Case - Control Study of Smoking and Death in India; NEJM, 2008

(2) World Health Organization. WHO Report on the Global Tobacco Epidemic, 2008. Geneva: World Health Organization; 2008 [cited 2008 Mar 21]. Available from: http://www.who.int/tobacco/mpower/en/

(3) Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008.

(4) Silagy et al. Nicotine replacement therapy for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, LTD.

(5) NICE. 2002. Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. Technology Appraisal Guidance - No.39.

(6) Centers for Disease Control and Prevention. Use of FDA-approved pharmacologic treatments for tobacco dependence. Morbidity and Mortality Weekly Report 2000; 49: 665-668.

    Contacts:  Mark Polisky
               GolinHarris
               00 +1+312+729+4417
               mpolisky@golinharris.com

               Jennifer May
               GlaxoSmithKline
               Consumer Healthcare
               00 +1+412+200+3729
               jennifer.l.may@gsk.com


'/>"/>
SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia
2. Activplant Corporation Announces Global Agreement with GlaxoSmithKline
3. GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
4. GlaxoSmithKlines Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL
5. GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding
6. GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance : – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases –
7. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
8. GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program
9. GlaxoSmithKline to Acquire the Leading Dry Mouth Brand, Biotene
10. AUDIO from Medialink and GlaxoSmithKline: Give Kids A Boost For Their Health!
11. GlaxoSmithKline Acquires Sirtris Pharmaceuticals, Inc., a World Leader in Sirtuin Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
Breaking Medicine Technology: